We propose to develop novel ErbB-targeted probes and assays to provide clinically applicable assessments of ErbB receptor function. in the setting of ErbB-targeted therapies. These tools include molecular probes using phage antibody-based technologies, cellular assay using micrometastasis detection technologies, and Imaging evaluations using MRI. and SPECT/PET -based technologies. Together, these are designed to provide powerful and complementary analyses of ErbB function, such as ErbB expression levels; interactions among ErbB members; receptor phosphorylation, signaling, internalization, and down modulation; ErbB biodistribution; and interactions with therapeutic ligands. These tools will be used in conjunction with new ErbB-targeted therapies, which encompass an important and expanding group of therapeutic strategies and agents. For example, ErbB2 (HER2, neu) has become a paradigm for targeted therapies, due to proof-of-concept with anti-ErbB2 MAb (trastuzumab/Herceptin); yet, the mechanism of action, resistance mechanisms, and predictive factors for this agent are poorly understood and controversial, and assessments of the """"""""model"""""""" antigen ErbB2 have turned out to be glaringly incomplete with existing methodologies. Our novel ErbB functional assessments will be used in preclinical and clinical studies to better understand the biological and mechanistic effects of various ErbB-targeted therapies, to monitor these effects over time, to predict response/resistance associated with treatment, and to provide validation and optimization of novel therapies. Our tools will facilitate early, mechanism-based assessments of these therapies. Our interdisciplinary molecular target assessment team consists of closely integrated projects and cores: Project 1, Detection, ErbB Characterization. and Molecular Profiling of Micrometastases to Assess ErbB- Targeted Agents (J, Park) Project2. Novel Phage Antibody-Based Probes of ErbB Function (J. Marks) . Project 3. Non-Invasive Imaging of ErbB Receptor-Ligand Interactions by Novel MRI and SPECT/PET Strategies (N. Hylton and H. VanBrocklin). Dev. Project 1, Development of Expression Array Analysis of ErbB-receptor Targeted Therapies (D. Tripathy). Dev. Project 2. PET -Based Assessments of Apoptosis (S. Taylor). Administrative Core (M. Tempero). Immunopathology Core (A. Thor). Pharmacology Core (D. Kirpotin). Given the prominent role of ErbB receptors in many cancer types and the many novel agents under active development to target these cancers, our ErbB-targeted assessments will have potentially wide applicability in cancer treatment. Also, the evaluation strategies to be developed here will serve as a model for the functional assessment of cell surface receptor-tyrosine kinases generally. Collaborating Institutions: Northwestern University; California Pacific Medical Center Research Institute; Lawrence Berkeley National Lab

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-SRRB-D (J2))
Program Officer
Jensen, Leeann T
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California San Francisco
Internal Medicine/Medicine
Schools of Medicine
San Francisco
United States
Zip Code
Lang, Julie E; Scott, Janet H; Wolf, Denise M et al. (2015) Expression profiling of circulating tumor cells in metastatic breast cancer. Breast Cancer Res Treat 149:121-31
Magbanua, Mark Jesus M; Sosa, Eduardo V; Roy, Ritu et al. (2013) Genomic profiling of isolated circulating tumor cells from metastatic breast cancer patients. Cancer Res 73:30-40
Magbanua, Mark Jesus M; Park, John W (2013) Isolation of circulating tumor cells by immunomagnetic enrichment and fluorescence-activated cell sorting (IE/FACS) for molecular profiling. Methods 64:114-8
Weng, Kevin C; Hashizume, Rintaro; Noble, Charles O et al. (2013) Convection-enhanced delivery of targeted quantum dot-immunoliposome hybrid nanoparticles to intracranial brain tumor models. Nanomedicine (Lond) 8:1913-25
Han, Ju; Chang, Hang; Giricz, Orsi et al. (2010) Molecular predictors of 3D morphogenesis by breast cancer cell lines in 3D culture. PLoS Comput Biol 6:e1000684
Lang, Julie E; Magbanua, Mark Jesus M; Scott, Janet H et al. (2009) A comparison of RNA amplification techniques at sub-nanogram input concentration. BMC Genomics 10:326
Peethambaram, Prema P; Melisko, Michelle E; Rinn, Kristine J et al. (2009) A phase I trial of immunotherapy with lapuleucel-T (APC8024) in patients with refractory metastatic tumors that express HER-2/neu. Clin Cancer Res 15:5937-44
Christine, C W; Starr, P A; Larson, P S et al. (2009) Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology 73:1662-9
Park, John W; Neve, Richard M; Szollosi, Janos et al. (2008) Unraveling the biologic and clinical complexities of HER2. Clin Breast Cancer 8:392-401
Weng, Kevin C; Noble, Charles O; Papahadjopoulos-Sternberg, Brigitte et al. (2008) Targeted tumor cell internalization and imaging of multifunctional quantum dot-conjugated immunoliposomes in vitro and in vivo. Nano Lett 8:2851-7

Showing the most recent 10 out of 25 publications